Company profile

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Privately held: no public share price (Suzhou, China-based CAR-T cell-therapy biotech. No public listing found via WebSearch (no ticker/exchange identified); recorded private per the default for an unlisted Chinese clinical-stage biotech rather than guessed. Sources: https://clinicaltrials.gov/study/NCT03999697 Entity resolved by asset-pipeline-v2.)

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
UTAA09
Phase 1
CD19
Systemic Lupus Erythematosus
UTAA91
Phase 1
CD19 (B cells) and PD-1+ pathogenic T cells
Systemic Lupus ErythematosusRheumatoid Arthritis
UTAA17
Preclinical
BCMACell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.